TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Weekly fruit and vegetable purchasing patterns
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients Achieving ASAS20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Mass in Kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean Body Mass in Kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total cost of 24-hour psychiatric services (12 months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cost of 24-hour psychiatric services (24 months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cost of 24-hour psychiatric services (36 months)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: First pass block of the cavo tricuspid isthmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of high-grade disease
Endpoint domain: Mortality/survival
Primary endpoint: Risk of low-grade disease
Endpoint domain: Mortality/survival
Primary endpoint: Change in Peak 6-Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of receiving at least 3 doses of nivolumab and completing surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Scar cosmesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Hepatic perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants infected with hepatitis B at 28 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Congenital defects and/or malformation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of mothers discontinuing TDF/TAF therapy due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: confirmed objective response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tumor mp-MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in airway seal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Metabolic signature of muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic signature of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic signature of satellite cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in 5-item Anorexia Symptom Subscale (5-IASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Comprehensive Developmental Inventory for Infants and Toddlers (CDIIT)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Abnormal Laboratory Measures of Safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic/Diastolic Flow Time Ratio of the Common Carotid Artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thyroid Lobe Volume Cutoff for Altered Flow Dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Assessment of skin color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain assessment using Wong-Baker Faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessment using FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile for bupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile for pioglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile for tolbutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile for omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile for midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Graft Failure at Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of newly formed mineralised bone tissue (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Measurement of the depth of analgesia using NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood, urine and tissue characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performance on Wisconsin card sorting test (WCST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on digit span test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Behavioral Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutrophil bacterialcidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Acute Infusion Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of medication errors
Endpoint domain: Adverse events/effects
Primary endpoint: Revision surgery due to recurrent subdural hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: C Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 100 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Daily Use of Cooling for Erythromelalgia-Related Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of BCC
Endpoint domain: Mortality/survival
Primary endpoint: AUCtau, Tmax and Cmax of PF-02545920 and PF-01001252
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration (Tmax; hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular sensitivity (MS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation and Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resolution of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change from International Cooperative Ataxia Rating Scale (ICARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants clinically affected by Parkinson's disease or Parkinsonism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence density of transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Health assessment questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Date of death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Utilized Smoking Cessation Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects Hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Daily Resting Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adherence to phosphate binders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Defect Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Heat Pain Threshold During Infusion in Non-Inflamed Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Heat Pain Threshold During Infusion in Inflamed Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mechanical Pain Threshold During Infusion in Non-Inflamed Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mechanical Pain Threshold During Infusion in Inflamed Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving complete or partial remission or no significant change in lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: lumen area of stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stent occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of HIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival free at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Reflux Impedance events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of disease-regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Linear length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccadic reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive measurements (threshold based)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive measurements (reaction time based)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: First aid performance after first aid course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First aid performance during first aid instructions by phone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal arterial blood pH at the start of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal arterial blood pH at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal arterial blood pH at 120 minutes after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Urinary Tract Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in Heart Rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Electrocardiogram Procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in T-Cell Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral Breast Tumor Recurrence Rates
Endpoint domain: Mortality/survival
Primary endpoint: Tumor Bed Recurrence Rates
Endpoint domain: Mortality/survival
Primary endpoint: Percent of Participants Experiencing Complications After Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in mean flow rate (mL/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total smoke intake (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure Re-hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effective Electrode Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concordance between Covid19 RT-PCR results and lung ultrasound results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of 5-ASA excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy on attention task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Examination (EDE-Q)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PANSS Total Score Mean Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Fixed Dental Prostheses With Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Significant reduction in pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dose-limiting toxicities (DLTs) of DCIKKb
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of DCIKKb
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of active VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of patients who adhere to oral targeted therapy treatment administration
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Nutrient status during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with COPD
Endpoint domain: Mortality/survival
Primary endpoint: Muscle strength test for lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The central activation and the excitability of motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage Total Weight Loss (%TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Bioavailability of SC XmAb7195
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Days Participants Measured Vitals and Completed Protocol Sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Health Sessions That Patients Measured and Recorded Vitals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean of sick days due to infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Histological Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Preterm Infant Skin Microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in plasma metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Short CNTB Summary Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in ADAS-Cog Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer Ratio for Each Vaccine Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bowel cleansing state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PK Cmax of a dose of [14C]BMS-986177
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK AUC(INF) of a dose of [14C]BMS-986177
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Tmax of a dose of [14C]BMS-986177
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients who performed the PET/MRI
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of patients called in for PET/MRI who have not realized the PET/MRI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of patients with good quality of the imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Pulmonary Artery Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire-Revised
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of YF476
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of YF476
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of YF476
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's usual sleep position
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Infant's position for last night's sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Patients With Treatment Emergent Adverse Events (TEAES)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Vital Signs: Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Grip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 5 Times Sit-to-Stand (STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Six-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gait Speed (m/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Late-Life Function and Disability Instrument (LLFDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intra-individual Difference in Reepithelialization of Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observer-rated depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in LDH Level at Week 25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hgb Level in the Absence of RBC Transfusion at Week 25
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Grade 3 and Grade 4 Adverse Events (AEs), And AEs Leading To Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Muscular force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Apnea-Hypopnea-Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microcirculatory perfusion alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal overall response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Incontinence Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) Score Dichotomized to 0-2 Versus Greater Than 2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death Due to Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Symptomatic Intracranial Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Median fluorescence intensity for cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Standard curves for cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Estimated pg/mL for cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrence of hiatal hernia or GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes